New hope for Tough-to-Treat blood cancer? scientists test promising drug
NCT ID NCT02302469
Summary
This study aimed to find a safe and effective dose of the drug lenalidomide for adults with Waldenstrom Macroglobulinemia, a rare and incurable blood cancer, whose disease had returned or was not responding to other therapies. It involved a small group of 17 participants to first test safety and then see if the drug could help control the cancer. The goal was to manage the disease, not cure it, by identifying a dose that patients could tolerate while still fighting the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH LENS
Lens, 62307, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier de la côte basque
Bayonne, 64109, France
-
Ch Clermond Ferrand
Clermont-Ferrand, 63000, France
-
Ch Nantes
Nantes, 44 093, France
-
Chru Lille
Lille, 59037, France
-
Groupe hospitalier Pitié Salpétrière
Paris, 75651, France
Conditions
Explore the condition pages connected to this study.